Steve Kafka, PhD

Dr. Steven Kafka joined Section 32 (S32) as Managing Partner in November 2019, bringing more than 20 years of experience in drug discovery, development, commercialization, and molecular diagnostics.…

• General Partner at Section 32

Loading the full interactive profile on VizierAtlas…